TrialSignal
Clinical trial intelligence report
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VTX958 in Participants With Moderately to Severely Active Crohn's Disease
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT05688852
Status
TERMINATED
Phase
PHASE2
Sponsor
Ventyx Biosciences, Inc
Executive brief
Investment-Ready Snapshot
This is a multicenter, randomized, double-blind placebo-controlled, parallel group study to evaluate the efficacy and safety of VTX958 in participants with moderately to severely active Crohn's Disease.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT05688852
Indication
Crohn Disease
Modality
small molecule
Target
VTX958, VTX958, VTX958 Placebo
Intervention
VTX958, VTX958, VTX958 Placebo
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.